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ABSTRACT 
Orthotopic liver transplantation has become the treat-
ment of choice for familial amyloidotic polyneuropathy. 
The aims of this study were to evaluate the renal com-
plications post orthotopic liver transplantation in familial 
amyloidotic polyneuropathy and their impact.
We retrospectively studied 185 recipients who 
underwent 217 orthotopic liver transplants. Mean 
age 36.8±9.5 years, 59% males, 14.3% with renal 
dysfunction pre orthotopic liver transplantation. Mean 
follow-up 3.6±3.7 years. Thirty-two patients died. 
Univariate and multivariate analysis were performed, 
and p<0.05 was considered significant.
Acute kidney injury occurred in 57 patients and 
renal replacement therapy was needed in 16/57. In 
multivariate analysis, acute kidney injury was cor-
related with development of chronic kidney disease 
(p<0.001).
Relating to development of chronic kidney disease, 
23.5% had progress to stage 3, 6% to stage 4 and 
5.1% to stage 5d. According to Spearmen correlation, 
risk factors for chronic kidney disease development 
were age (p<0.001), renal dysfunction pre orthotopic 
liver transplantation (p<0.001) and acute kidney injury 
post orthotopic liver transplantation (p<0.001).
Mortality was correlated with age (p<0.001), re-
transplantation need (p=0.004), renal dysfunction 
pre orthotopic liver transplantation (p<0.001), acute 
kidney injury post orthotopic liver transplantation 
(p=0.04), and chronic kidney disease stage 5 (p<0.001). 
Using binary regression, mortality was correlated with 
chronic kidney disease development (p=0.02).
In conclusion, familial amyloidotic polyneuropathy 
patients are disposed to renal complications that 
have a negative impact on the survival of these 
patients.
Key-Words:
Familial amyloidotic polyneuropathy; liver transplan-
tation; mortality; renal dysfunction.
INTRODUCTION 
Familial amyloidotic polyneuropathy (FAP) is a 
systemic amyloidotic disease, inherited in an auto-
somal dominant mode1,2. This disease is due to 
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a mutant gene in chromosome pair 18 that codi-
fies transthyretin (TTR) protein1,2. To date, more 
than 80 amyloidogenic TTR variants have been 
described3. In Type I (Portuguese, Swedish and 
Japanese variant), the most frequent form, firstly 
described by Corino de Andrade4,5, there is an 
amino acid substitution of methionine for valine 
at position 30 (V30M) of the TTR molecule1-3,6,7. 
This amino acid substitution leads to TTR protein 
instability that gives rise to insoluble fibres with 
β-sheet structures, which are deposited in the 
extra-cellular matrix as amyloid aggregates. How-
ever, the mutate form is not truly necessary for 
the amyloid deposits, since wild type is found in 
senile amydoidosis2.
The Portuguese type is severe, and the amyloid 
deposits are diffusely distributed in the peripheral 
nervous system of FAP patients1. The symptoms start 
in the lower extremities, with spontaneous pains, 
numbness and loss of temperature sensations that 
extend above ankle level. Motor deficit also occurs, 
with loss of balance and stepping gait3. There is a 
progression of the disease with a multisystemic 
involvement: peripheral sensorimotor polyneuropa-
thy, autonomic dysfunction causing orthostatic hypo-
tension, cardiac arrhythmias, gastrointestinal dysmo-
t i l i ty, erect i le dysfunction and sphincter 
disturbances1-3,8. Renal involvement is common. All 
patients have amyloid deposits in the kidney, but 
not all will have nephropathy1. FAP nephropathy has 
special epidemiological features and only one third 
of the patients develop chronic kidney disease (CKD) 
and 10% progress to CKD stage 5d1.
Without treatment, the patients die after eight to 
ten years, following the development of muscular 
atrophy, severe autonomic neuropathy and malnutri-
tion9,10. Because more than 90% of the mutant pro-
tein is produced by the liver, orthotopic liver trans-
plantation (OLT) has been proposed to treat this 
disease. The first OLT for treatment of FAP patients 
was performed in 1990 by Holmgren11. Follow-up of 
these patients was successful, and it is considered 
to date an effective treatment in clinical management 
of the disease12-14.
After OLT, kidney disease is a very important prob-
lem, and this complication significantly compromises 
patient outcome15-17 and increases mortality risk18-20. 
Several factors, such as the presence of renal 
dysfunction pre OLT, the use of calcineurin inhibitors 
and the development of hypertension or diabetes 
could exacerbate kidney function15,18,19.
The aims of this study were to evaluate the inci-
dence of renal complications post OLT in patients 
with FAP, to identify possible risk factors and to 
determine the impact on patient survival.
PATIENTS AND METHODS 
Study design 
This was a retrospective study of 185 FAP patients 
submitted to 217 OLT in our unit over a fifteen-year 
time period. Data were collected at day 0, 1, 7 and 
21, at 6 months, 12 months and yearly after trans-
plantation, up to the end of the study.
Clinical data included age, gender, weight, pres-
ence of diabetes mellitus, hypertension, hepatitis B 
and C infection, immunosuppression and need for 
acute renal replacement therapy (RRT). Laboratory 
data included serum creatinine (Scr) values and/or 
glomerular filtration rate (GFR), estimated by Cock-
croft-Gault equation.
Renal dysfunction before transplantation (RD pre 
OLT) was defined by GFR ≤60ml/min or Scr ≥1.5 mg/
dl. There were no records concerning proteinuria/
microalbuminuria in patients’ clinical files.
Acute kidney injury (AKI) was defined according 
to the RIFLE criteria21 as a persistent decrease in 
renal function for at least three days using the worst 
value for renal function in that period.
At the end of follow-up and depending on the 
last value of GFR, renal function was classified accord-
ing to the K/DIGO Clinical Practice Guidelines22.
Patients submitted to simultaneous liver and kid-
ney transplants were excluded from this study.
Biochemical analysis 
Biochemical analysis was performed using stan-
dard laboratory methods.
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Immunosuppression protocols 
Over the fifteen-year period, different immunosup-
pressive protocols were used. Induction protocols with 
ATG or basiliximab were rarely employed until 2007. 
Steroids were usually applied in all patients for the 
first months (20 mg/day), and slowly diminished up 
to twelve months. The association of ciclosporin and 
azathioprine were used in the majority of recipients 
up to 2003, and, since then, tacrolimus and MMF 
have been used. Since 2001, sirolimus has been used 
in a limited number of recipients. The use of ciclosporin, 
tacrolimus, sirolimus, azathioprine or MMF was con-
sidered as a dichotomous variable (yes or no).
Statistical analysis 
Data are presented as mean±SD values for normally 
distributed variables or as frequencies for categorical 
variables. Independent variables were compared using 
the Mann Whitney and the chi square tests. Correlations 
between variables were studied with Spearman correla-
tion test for univariate analysis, and by binary regression 
for multivariate analysis (confidence interval of 95%), 
with forward method. All tests were performed using 
the SPSS system 15.0 (SPSS Inc., Chicago, IL) and a 
p< 0.05 was considered statistically significant.
RESULTS 
Table I shows the clinical characteristics of our popu-
lation. Up to 2007, 217 FAP patients were transplanted 
in our unit, with a mean follow-up of 3.6±3.7 years, 
with 28.6% (n=62/217) having more than five years 
and 8.8% (n=19/207) more than ten years of follow-up. 
These patients were predominantly young males, with 
a global mean age of 36.8±9.5 years. Arterial hyperten-
sion was present in only 17 patients and a minority 
was diabetic (n=2) or HCV (n=2) infected patients. 
There was no HBV infection among these patients. 
Re-transplantation was needed in 14.7% (n=32), due 
predominantly to thrombotic complications.
Renal dysfunction before transplantation 
RD pre OLT was known in 14.3% (n=31) of the 
recipients. These patients were older (r=0.3; p<0.0001) 
and this finding was more frequent in women (r=0.3, 
p<0.0001) and in hypertensive patients (r=0.2; 
p=0.01). There was no correlation between the pres-
ence of RD pre OLT and diabetes or HCV infection.
Using Spearman correlation, RD pre OLT was asso-
ciated with F criteria of AKI classification (r=0.2, 
p=0.02), CKD development (r=0.5, p<0.001): stage 
3 (r=0.4; p<0.001), stage 4 (r=0.2; p=0.03), stage 
5d (r=0.2; p=0.01), with RRT requirement (r=0.2; 
p=0.003) and with mortality (r=0.2; p=0.002). For 
multivariate analysis, adjusting for age, gender, and 
for AKI post transplant, it was significantly correlated 
with development of CKD (p<0.001).
Acute kidney injury (AKI) 
AKI was observed in 57 (26.3%) patients (Table II), 
predominantly in women (r=0.2; p=0.02). Acute RRT 
was needed in 16/57 patients (r=0.4; p<0.001). Only a 
minority recovered their renal function, with a GFR ≥60ml/
min (r=-0.5; p<0.001): 25 (43.8%) developed CKD stage 
3 (r=0.3; p<0.001), 9 (15.8%) developed CKD stage 4 
(r=0.3; p<0.001), and 8 (14%) of these patients are on 
haemodialysis (r=0.2; p<0.001); 13 (22.8%) patients died 
Table I
Clinical characteristics of the population
Variable OLT (n=217)
Age (yr) 36.8±9.5
Gender
Male
Female
128 (59%)
89 (41%)
Diabetes (%) 0.9% (2)
Arterial Hypertension (%) 7.8% (17)
Hepatitis C virus infection (%)
Hepatitis B virus infection (%)
0.9% (2)
0%
Renal dysfunction pre transplantation
Acute kidney injury
Chronic kidney disease
Stage 3
Stage 4
Stage 5
14.3% (31)
26.3% (57)
34.6% (75)
23.5% (50)
6% (13)
5.1% (11)
Re-transplantation (%) 14.7% (32) 
Mean follow-up time (yr) 3.6 ±3.7
Mortality (%) 14.7% (32)
Immunosuppression (%)
With Ciclosporin
With Tacrolimus
With Sirolimus
44.5%
49.2%
6.3%
OLT (orthotopic liver transplantation).
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(r=0.1; p=0.04) In multivariate analysis, adjusting for 
age and for presence of renal dysfunction before OLT, 
AKI correlated with development of CKD (p<0.001).
Chronic kidney disease (CKD) 
According to KDOQI definitions, 34.6% (n=75/217) of 
the recipients developed CKD, with 51 patients (23.5%) 
attaining a stage 3, 13 patients (6%) a stage 4 and 11 
patients (5.1%) attaining a stage 5d (Table II).
In univariate analysis, RD pre OLT (r=0.5; p<0.001) 
and AKI post OLT (r=0.5; p<0.001), as mentioned, were 
risk factors for CKD development in all three stages. 
Age (r=0.3; p<0.001) was also a risk factor for CKD 
development, especially in stages 4 and 5d (r=0.2; 
p=0.003; r=0.2; p=0.008; respectively), and acute RRT 
requirement (r=0.4; p<0.001), specially in stage 5 (r=0.8; 
p<0.001). Arterial hypertension was found to be a risk 
factor for CKD stage 4 (r=0.3; p<0.0001), and diabetes 
a risk factor for stage 5 (r=0.2; p=0.001). CKD was 
associated with increased mortality (r=0.2; p=0.001), 
and this observation had particularly impact on patients 
with CKD stage 5d (r=0.4; p<0.001). There were no 
correlations between immunosuppression protocols and 
CKD other than a beneficial effect of tacrolimus (r=-0.2; 
p=0.03) on chronic renal dysfunction.
In multivariate analysis, and adjusting for age, RD 
pre OLT, and AKI post OLT, CKD correlated with 
mortality (p=0.02).
Mortality 
By the end of follow-up, 32 (14.7%) FAP patients 
died, with a mean follow-up of 1.8±3.2 years (r=-0.3; 
p<0.001). Follow-up time was shorter in older patients 
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Table II
Clinical characteristics of the population according to the presence or absence of AKI or CKD
AKI
(n=57)
No AKI
(n=160)
CKD
(n=75)
No CKD
(n=142)
Mean age (yr) 37.5±10.1 36.6±9.3 40.2±10.4 35.1±8.6
Male gender (%) 45.6% (26) 63.8% (102) 45.3% (34) 66.2% (94)
Diabetes (%) 0% 1.3% (2) 2.7% (2) 0%
Arterial hypertension (%) 14% (8) 5.6% (9) 12% (9) 5.6% (8)
Hepatitis C virus infection (%) 0% 1.3% (2) 0% 1.4% (2)
Renal dysfunction pre OLT (%) 21.1% (12) 11.9% (19) 37.3% (28) 2.1% (3)
Acute kidney injury (%) 100% 0% 52% (39) 11.3% (16)
CKD
Stage 3
Stage 4
Stage 5
73.7% (42)
43.9% (25)
15.8% (9)
14% (8)
20.6% (33)
16.3% (26)
2.5% (4)
1.9% (3)
100%
68% (51)
17.3% (13)
14.7% (11)
0%
Re-transplantation (%) 21.1% (12) 12.5% (20) 20% (15) 12% (17)
Mean follow-up time (yr) 3.3±3.6 3.7±3.7 4.3±4.3 3.2±3.3
Mortality (%) 22.8% (13) 11.9% (19) 25.3% (19) 9.2% (13)
AKI (acute kidney injury); CKD (chronic kidney disease).
Table III
Multivariate analysis for CKD development
CKD development
β CI 95% p R2
RD pre OLT 3.5 8.2 to 127.6 <0.001
0.6Age 0.7 1 to 1.1  0.003
Gender 0.2 0.5 to 2.8 0.6
AKI post OLT 2.8 6.5 to 37.7 <0.001
AKI 2.8 6.5 to 38.8 <0.001
0.6Age 0.7 1 to 1.1  0.002
RD pre OLT 3.5 8.2 to 131.2 <0.001
CKD (chronic kidney disease); AKI post OLT (acute kidney injury post orthotopic liver 
transplantation);
RD pre OLT (renal dysfunction pre orthotopic liver transplantation).
Table IV
Multivariate analysis for mortality
Mortality
β CI 95% p R2
CKD development 1.9 1.2 to 38.2 0.02
0.3 Age 0.004 0.9 to 1  0.2
 AKI post OLT 0.6 0.5 to 6 0.4
 RD pre OLT 1 0.9 to 9.2 0.08
AKI post OLT (acute kidney injury post orthotopic liver transplantation); CKD (chronic 
kidney disease);
RD pre OLT (renal dysfunction pre orthotopic liver transplantation).
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(r=-0.2; p=0.009) and in re-transplanted patients 
(r=-0.3; p=0.001).
According to our results, in univariate analysis 
mortality was associated with age (r=0.3; p<0.001) 
and need for re-transplantation (r=0.2; p=0.004).
Mortality was also linked to renal dysfunction, 
including renal dysfunction pre OLT (r=0.3, p<0.001); 
AKI post OLT (all classes: r=0.2; p=0.04; F class: 
r=0.1; p=0.03) and CKD development (all stages: 
r=0.2; p=0.001; stage 5: r=0.4; p<0.001).
Using binary regression, mortality was correlated 
with CKD development (p=0.02).
DISCUSSION 
Liver transplantation is expected to cause a partial 
regression or stabilisation in the majority of symp-
toms in FAP patients. In fact, the neurological symp-
toms stabilise, but there is usually no significant 
improvement13. In addition, OLT must be performed 
early, prior to the development of malnutrition, which 
is associated with high morbidity and mortality10. 
Nephropathy, as demonstrated by the presence of 
microalbuminuria or overt proteinuria, develops con-
comitantly with progression of the neurological dis-
ease, but occasionally may be present from the 
beginning and may affect one third to 75% of the 
patients23. Recently, it has been shown that patients 
with normal renal function and low levels of pro-
teinuria have slow progression to ESRD, irrespective 
of the duration of their neuropathy24.
Renal dysfunction appears to be an important 
issue after OLT transplantation, as it is associated 
with higher mortality. Our study evaluates the long-
term impact on renal function in 185 FAP patients 
submitted to 217 OLT procedures. There was a male 
preponderance, as is usual in FAP patients, and the 
mean age was 36.8±9.5 years. In Portugal mean age 
of onset of the disease is 33.5±9.5 years2 and this 
difference probably reflects listing time.
In our study, kidney dysfunction established by 
glomerular filtration rate, not by the presence of 
proteinuria/microalbuminuria, was present in 14% by 
the time of OLT. Of note, this proportion may be 
certainly higher, as renal functional status in FAP 
patients can be underdiagnosed, due to malnutrition 
and reduced muscular mass, and this contributes to 
false lower Scr levels. However, it may be used to 
follow changes of renal function, as the BMI remains 
constant after OLT. Patients with RD pre OLT were 
predominantly female gender. Other groups have 
also shown that female gender is a risk factor for 
the development of CKD in FAP patients1,2. Signifi-
cantly, patients presenting with RD pre OLT were at 
higher risk of developing AKI and CKD after OLT, 
and had a higher risk of mortality.
These findings impose a question: renal function 
pre OLT predicts an increased risk of postoperative 
renal failure, infection and death. This item, in many 
of these studied patients, is overestimated. We can 
conclude that in some patients a hidden risk with 
major consequences exists. Perhaps some patients 
would benefit from liver-kidney transplantation 
(LKTx), as haemodialysis dependence is higher in 
RD pre OLT patients. In this case, simultaneous LKTx 
has potential advantages; it avoids the progression 
of systemic manifestations of amyloidosis, avoids 
recurrence of renal amyloidosis and avoids the need 
for haemodialysis, providing a long-term substitution 
therapy for renal failure25,26. There are published 
articles recommending combined LKTx for CKD stage 
5d in FAP TTR Val30Met25,26.
There is little published data, and appropriate cri-
teria for simultaneous LKTx both in acute and chronic 
kidney diseases are being studied. The Consensus 
Conference on Simultaneous Liver Kidney Transplan-
tation Review Board has proposed the following 
indications27: 1) end stage renal disease and symp-
tomatic portal hypertension; 2) liver failure and CKD 
below 30 ml/min; 3) AKI with Scr 2 mg/dl and dialysis 
for more than 8 weeks; 4) liver failure and CKD with 
more than 30% of glomerulosclerosis / fibrosis. Look-
ing at these criteria, combined LKTx in FAP should 
be proposed to some patients on the topic of their 
renal function pre OLT. Nevertheless, it is important 
to note that patients with amyloidosis undergoing 
renal transplantation tolerate complications poorly 
and are at high risk of dying within the first three 
months, and autonomic neuropathy causing urinary 
retention is an additional difficulty in kidney trans-
plantation26. As it is a complex surgical procedure, 
immediate post transplantation time is crucial to its 
good outcome. In the long-term, hepatitis C virus 
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infection, panel reactive antibody > 20% and female 
donor gender are contributing factors for unfavour-
able outcomes28.
AKI was observed in 26.3% of the patients after 
OLT. The development of AKI was a poor prognosis 
factor, as it was correlated with CKD. Indeed almost 
74% remained with CKD.
Overall, CKD affected 34.6% patients. Hyperten-
sion, diabetes, need of RRT, RD pre OLT and AKI 
were risk factors for the development of different 
stages of CKD. Immunosuppressive protocols may 
impact on renal function; in reality one of the most 
important causes for CKD post OLT is calcineurin 
inhibitor toxicity, and this emphasises the need for 
calcineurin inhibitor minimisation protocols post 
transplant. In this population, mortality was corre-
lated with CKD stage 5. Mortality was additionally 
correlated with age, re-transplantation and with renal 
dysfunction prior to OLT and with AKI, mainly with 
severe AKI, defined by F class.
Despite these results there are some limitations 
to our study. Firstly, renal dysfunction was only 
acceded by Scr, as there were no records regarding 
proteinuria, and this is an important tool to access 
nephropathy. Secondly this is a retrospective study, 
with all those drawbacks.
In conclusion, CKD development after OLT was 
observed in one third of our population and renal 
failure was associated with mortality. These results 
reinforce the need for early OLT for better outcome 
and inevitable referral to the nephrologists when 
there is impairment of renal function. As mortality 
was higher when there was renal dysfunction, we 
can conclude that renal complications are important 
prognostic tools in these patients.
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